

118TH CONGRESS
1ST SESSION

H. R. 5027

To improve the understanding of, and promote access to treatment for,
chronic kidney disease, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

JULY 27, 2023

Mrs. MILLER of West Virginia (for herself and Ms. SEWELL) introduced the following bill; which was referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To improve the understanding of, and promote access to
treatment for, chronic kidney disease, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE; TABLE OF CONTENTS.**

4 This Act may be cited as the “Chronic Kidney Dis-
5 ease Improvement in Research and Treatment Act of
6 2023”.

1 **TITLE I—PREVENTING KIDNEY**
 2 **DISEASE AND EXPANDING**
 3 **AWARENESS AND EDUCATION**

4 **SEC. 101. EXPANDING MEDICARE ANNUAL WELLNESS BEN-**
 5 **EFIT TO INCLUDE KIDNEY DISEASE SCREEN-**
 6 **ING.**

7 (a) IN GENERAL.—Section 1861(ww)(2) of the Social
 8 Security Act (42 U.S.C. 1395x(ww)(2)) is amended—

9 (1) by redesignating subparagraph (O) as sub-
 10 paragraph (P); and

11 (2) by inserting after subparagraph (N) the fol-
 12 lowing new subparagraph:

13 “(O) Chronic kidney disease screening as
 14 defined by the Secretary.”.

15 (b) EFFECTIVE DATE.—The amendments made by
 16 this section apply to items and services furnished on or
 17 after January 1, 2022.

18 **SEC. 102. INCREASING ACCESS TO MEDICARE KIDNEY DIS-**
 19 **EASE EDUCATION BENEFIT.**

20 (a) IN GENERAL.—Section 1861(ggg) of the Social
 21 Security Act (42 U.S.C. 1395x(ggg)) is amended—

22 (1) in paragraph (1)—

23 (A) in subparagraph (A), by inserting “or
 24 stage V” after “stage IV”; and

(B) in subparagraph (B), by inserting “or of a physician assistant, nurse practitioner, or clinical nurse specialist (as defined in section 1861(aa)(5)) assisting in the treatment of the individual’s kidney condition” after “kidney condition”; and

(2) in paragraph (2)—

(A) by striking subparagraph (B); and

(B) in subparagraph (A)—

(i) by striking “(A)” after “(2)”;

(ii) by striking “and” at the end of clause (i);

(iii) by striking the period at the end of clause (ii) and inserting “; and”;

(iv) by redesignating clauses (i) and (ii) as subparagraphs (A) and (B), respectively; and

(v) by adding at the end the following:

“(C) a renal dialysis facility subject to the requirements of section 1881(b)(1) with personnel who—

“(i) provide the services described in paragraph (1); and

“(ii) is a physician (as defined in subsection (r)(1)) or a physician assistant,

1 nurse practitioner, or clinical nurse spe-
 2 cialist (as defined in subsection (aa)(5)).”.

3 (b) PAYMENT TO RENAL DIALYSIS FACILITIES.—
 4 Section 1881(b) of the Social Security Act (42 U.S.C.
 5 1395rr(b)) is amended by adding at the end the following
 6 new paragraph:

7 “(15) For purposes of paragraph (14), the sin-
 8 gle payment for renal dialysis services under such
 9 paragraph shall not take into account the amount of
 10 payment for kidney disease education services (as
 11 defined in section 1861(ggg)). Instead, payment for
 12 such services shall be made to the renal dialysis fa-
 13 cility on an assignment-related basis under section
 14 1848.”.

15 (c) EFFECTIVE DATE.—The amendments made by
 16 this section apply to kidney disease education services fur-
 17 nished on or after January 1, 2022.

18 **TITLE II—INCENTIVIZING** 19 **KIDNEY CARE INNOVATION**

20 **SEC. 201. REFINING THE END-STAGE RENAL DISEASE PAY-** 21 **MENT SYSTEM TO IMPROVE ACCURACY IN** 22 **PAYMENT AND SUPPORT THERAPIES.**

23 (a) IN GENERAL.—Section 1881(b)(14) of the Social
 24 Security Act (42 U.S.C. 1395ww(b)(14)) is amended by
 25 adding the following new subparagraph:

1 “(J) PAYMENT FOR NEW AND INNOVATIVE
2 DRUGS, BIOLOGICALS, AND DEVICES THAT ARE
3 RENAL DIALYSIS SERVICES.—

4 “(i) IN GENERAL.—For drugs or
5 biologicals defined as within a functional
6 category and furnished on or after Janu-
7 ary 1, 2024, the Secretary shall implement
8 an add-on adjustment for claims that in-
9 clude such drugs or biologicals that, among
10 other things, shall—

11 “(I) calculate a per-treatment
12 cost using the most recent cost and
13 utilization data collected during a
14 transitional payment period of not less
15 than 3 years by dividing the total
16 spending for such drug or biological
17 during such transitional period by the
18 total number of treatments for which
19 such drug or biological was listed on
20 such claim during such period of time;

21 “(II) offset the amount of the
22 add-on adjustment by an amount that
23 corresponds with the reduction in ex-
24 penditures for other formerly sepa-
25 rately billed renal dialysis drugs that

1 were directly the result of the inclu-
2 sion of the new product;

3 “(III) update the add-on adjust-
4 ment annually to account for infla-
5 tionary changes; and

6 “(IV) be applied immediately
7 upon the expiration of the TDAPA
8 period for a product to avoid a gap
9 between the TDAPA and availability
10 of the post-TDAPA add-on adjust-
11 ment.

12 “(ii) IMPLEMENTATION.—This policy
13 shall not be implemented in a budget neu-
14 tral manner.”.

15 (b) NEW DEVICES AND OTHER TECHNOLOGIES.—As
16 part of the promulgation of the annual rule for the Medi-
17 care end-stage renal disease prospective payment system
18 under section 1881(b)(14) of the Social Security Act (42
19 U.S.C. 1395rr(b)(14)) for calendar year 2022, and in con-
20 sultation with stakeholders, the Secretary of Health and
21 Human Services (in this section referred to as the “Sec-
22 retary”) shall ensure that the single payment amount is
23 adequate to cover the cost of the new innovative device
24 or other technology with substantial clinical improvement
25 and increase the single payment amount if the Secretary

1 determines such payment amount is not adequate to cover
 2 such cost. In carrying out the preceding sentence, the Sec-
 3 retary shall use the cost and utilization data collected dur-
 4 ing a 3-year transitional payment period, as otherwise de-
 5 scribed in the final regulation published on November 9,
 6 2020 (85 Fed. Reg. 71398 et seq.).

7 **SEC. 202. ENSURING MEDICARE ADVANTAGE SUPPORTS**
 8 **KIDNEY CARE INNOVATIVE THERAPIES.**

9 Section 1853(c) of the Social Security Act (42 U.S.C.
 10 1395ww–23(c)) is amended by adding the following new
 11 paragraph:

12 “(8) **ADJUSTMENT FOR INNOVATIVE PRODUCTS**
 13 **FOR ENROLLES WITH END STAGE RENAL DIS-**
 14 **EASE.**—If the Secretary makes a determination with
 15 respect to the application of the End Stage Renal
 16 Disease Transitional Drug Add-On Payment Adjust-
 17 ment or the Transitional Add-on Payment Adjust-
 18 ment for New and Innovative Equipment and Sup-
 19 plies to a product under this title that will result in
 20 an increase in the costs to Medicare+Choice of pro-
 21 viding benefits under contracts under this part for
 22 the period of the Transitional Drug Add-On Pay-
 23 ment Adjustment or the Transitional Add-on Pay-
 24 ment Adjustment for New and Innovative Equip-
 25 ment and Supplies, the Secretary shall directly make

1 the payments adjustments to providers of services or
2 independent dialysis facilities consistent with the ap-
3 plication of such adjustments under the ESRD pro-
4 spective payment system outlined in section
5 1881(b)(14) of this title for the complete duration
6 that the adjustment applies under such section.
7 After the duration of such adjustment, the Secretary
8 shall adjust appropriately the payments to such or-
9 ganizations under this part.

10 “(9) POST-TDAPA PAYMENT ADD-ON ADJUST-
11 MENT.—The Secretary shall require providers of
12 services or independent dialysis facilities to apply the
13 adjustment required under subparagraph (J) of sec-
14 tion 1881(b)(14) to payments made under this
15 part.”.

16 **SEC. 203. IMPROVING PATIENT LIVES AND QUALITY OF**
17 **CARE THROUGH RESEARCH AND INNOVA-**
18 **TION.**

19 (a) STUDY.—The Secretary of Health and Human
20 Services (in this section referred to as the “Secretary”)
21 shall conduct a study on increasing kidney transplantation
22 rates. Such study shall include an analysis of each of the
23 following:

24 (1) Any disincentives in the payment systems
25 under the Medicare program under title XVIII of

1 the Social Security Act (42 U.S.C. 1395 et seq.)
2 that create barriers to kidney transplants and post-
3 transplant care for beneficiaries with end-stage renal
4 disease.

5 (2) The practices used by States with higher
6 than average donation rates and whether those prac-
7 tices and policies could be successfully utilized in
8 other States.

9 (3) Practices and policies that could increase
10 deceased donation rates of minority populations.

11 (4) Whether cultural and policy barriers exist to
12 increasing living donation rates, including an exam-
13 ination of how to better facilitate chained donations.

14 (5) Other areas determined appropriate by the
15 Secretary.

16 (b) REPORT.—Not later than 18 months after the
17 date of the enactment of this Act, the Secretary shall sub-
18 mit to Congress a report on the study conducted under
19 subsection (a), together with such recommendations as the
20 Secretary determines to be appropriate.

1 **TITLE III—ADDRESSING THE**
2 **KIDNEY CARE WORKFORCE**
3 **CRISIS**

4 **SEC. 301. ENSURING ACCURACY AND STABILITY IN KIDNEY**
5 **CARE PAYMENT.**

6 Section 1881(b)(14) of the Social Security Act (42
7 U.S.C. 1395ww(b)(14)) is amended by adding the fol-
8 lowing new subparagraph:

9 “(K) Beginning with calendar year 2024,
10 the Secretary shall compute an adjustment to
11 the annual update of the previous calendar
12 year’s rate to account for forecast error. The
13 initial adjustment (in calendar year 2024) to
14 the update of the previous calendar year’s rate
15 will take into account the cumulative forecast
16 error between calendar years 2021 and 2022.
17 Subsequent adjustments in succeeding fiscal
18 years will take into account the forecast error
19 from the most recently available calendar year
20 for which there is final data. The forecast error
21 adjustment shall apply whenever the difference
22 between the forecasted and actual percentage
23 change in the ESRD market basket index ex-
24 ceeds the threshold of 0.5 percentage points.”.

1 **SEC. 302. ENCOURAGING KIDNEY CARE WORKFORCE IN**
 2 **UNDER SERVED AREAS.**

3 (a) DEFINITION OF PRIMARY CARE SERVICES.—Sec-
 4 tion 331(a)(3)(D) of the Public Health Service Act (42
 5 U.S.C. 254d(a)(3)(D)) is amended by inserting “renal di-
 6 alysis,” after “dentistry,”.

7 (b) NATIONAL HEALTH SERVICE CORPS SCHOLAR-
 8 SHIP PROGRAM.—Section 338A(a)(2) of the Public Health
 9 Service Act (42 U.S.C. 254l(a)(2)) is amended by insert-
 10 ing “, which may include nephrology health professionals”
 11 before the period at the end.

12 (c) NATIONAL HEALTH SERVICE CORPS LOAN RE-
 13 PAYMENT PROGRAM.—Section 338B(a)(2) of the Public
 14 Health Service Act (42 U.S.C. 254l–1(a)(2)) is amended
 15 by inserting “, which may include nephrology health pro-
 16 fessionals” before the period at the end.

17 **TITLE IV—EXPANDING PATIENT**
 18 **CHOICE OF COVERAGE**

19 **SEC. 401. MEDIGAP COVERAGE FOR BENEFICIARIES WITH**
 20 **END-STAGE RENAL DISEASE.**

21 (a) GUARANTEED AVAILABILITY OF MEDIGAP POLI-
 22 CIES TO ALL ESRD MEDICARE BENEFICIARIES.—

23 (1) IN GENERAL.—Section 1882(s) of the So-
 24 cial Security Act (42 U.S.C. 1395ss(s)) is amend-
 25 ed—

26 (A) in paragraph (2)—

1 (i) in subparagraph (A), by striking
 2 “is 65” and all that follows through the
 3 period and inserting the following: “is—

4 “(i) 65 years of age or older and is
 5 enrolled for benefits under part B; or

6 “(ii) entitled to benefits under
 7 226A(b) and is enrolled for benefits under
 8 part B.”; and

9 (ii) in subparagraph (D), in the mat-
 10 ter preceding clause (i), by inserting “(or
 11 is entitled to benefits under 226A(b))”
 12 after “is 65 years of age or older”; and
 13 (B) in paragraph (3)(B)—

14 (i) in clause (ii), by inserting “(or is
 15 entitled to benefits under 226A(b))” after
 16 “is 65 years of age or older”; and

17 (ii) in clause (vi), by inserting “(or
 18 under 226A(b))” after “at age 65”.

19 (2) EFFECTIVE DATE.—The amendments made
 20 by paragraph (1) shall apply to Medicare supple-
 21 mental policies effective on or after January 1,
 22 2022.

23 (b) ADDITIONAL ENROLLMENT PERIOD FOR CER-
 24 TAIN INDIVIDUALS.—

25 (1) ONE-TIME ENROLLMENT PERIOD.—

1 (A) IN GENERAL.—In the case of an indi-
2 vidual described in subparagraph (B), the Sec-
3 retary of Health and Human Services shall es-
4 tablish a one-time enrollment period during
5 which such an individual may enroll in any
6 Medicare supplemental policy under section
7 1882 of the Social Security Act (42 U.S.C.
8 1395ss) of the individual’s choosing.

9 (B) ENROLLMENT PERIOD.—The enroll-
10 ment period established under subparagraph
11 (A) shall begin on January 1, 2023, and shall
12 end June 30, 2023.

13 (2) INDIVIDUAL DESCRIBED.—An individual de-
14 scribed in this paragraph is an individual who—

15 (A) is entitled to hospital insurance bene-
16 fits under part A of title XVIII of the Social
17 Security Act under section 226A(b) of such Act
18 (42 U.S.C. 426–1);

19 (B) is enrolled for benefits under part B of
20 such title XVIII; and

21 (C) would not, but for the provisions of,
22 and amendments made by, subsection (a) be eli-
23 gible for the guaranteed issue of a Medicare
24 supplemental policy under paragraph (2) or (3)

1 of section 1882(s) of such Act (42 U.S.C.
2 1395ss(s)).

○